DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20150166

Role of voglibose in prevention of type 2 diabetes in established case of impaired glucose tolerance: an observation study

Mohammed Riyaz, Imran S, Nidhisha K. Joseph, Maryam Saba

Abstract


Background: The increased prevalence of type 2 diabetes mellitus is a major concern for the health providers. We have done an observation study in the diagnosed IGT patient who received α-glucosidase inhibitor (voglibose), which could prevent the development of type 2 diabetes in high-risk individuals.

Methods: This study was an observational study comprising of voglibose and placebo in individuals with impaired glucose tolerance.66 eligible patients were on the standard diet and taking regular exercise with impaired glucose tolerance were randomly assigned to oral voglibose 0.2 mg three times a day (n=66) or placebo (n=60) in this study. Treatment was continued until participants developed type 2 diabetes (primary endpoint) or normoglycaemia (secondary endpoint).

In the final analysis, 66 registered individuals fulfilled the inclusion criteria: 36 were randomly assigned to receive voglibose and 30 placebos (two participants in the placebo group did not take their medication and were excluded). 

Results: The mean duration of treatment was 48.3 weeks (SD: 36.4), i.e., 45.4 weeks (34.7) for voglibose and 51.7 weeks (37.4) for placebo. Voglibose was better than placebo (p= 0.0024) in individuals treated for an average of 48.3 weeks (SD 36.4). Patients treated with voglibose had a lower risk of progression to type 2 diabetes than did those on placebo. More people in the voglibose group achieved normoglycaemia than did those in the placebo group.

Conclusion: Voglibose, in addition to lifestyle modification, can reduce the development of type 2 diabetes in high risk individuals with impaired glucose tolerance.

 


Keywords


Voglibose, Diabetes mellitus, IGT, Impaired glucose tolerance, Prevention

Full Text:

PDF

References


International Diabetes Federation [Internet] Belgium: Diabetes facts and figures, Inc.; 2014. Available at: http://www.idf.org/diabetesatlas/ update-2014. Accessed 10 Dec 2014.

The DECODE Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617–21.

Alberti KGMM, et.al. The clinical implications of impaired glucose tolerance. Diabet Med 1996; 13: 927–37.

Ramachandran A, Snehalatha C, Mary S, et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006; 49: 289–97.

Kosaka K, Noda M, Kuzuya T, et.al. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152–62.

Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: a 20-year follow-up study. Lancet 2008; 371: 1783–89.

Pan X-R, Li G-W, Hu Y-H, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997; 20: 537–44.

Eckel RH, Grundy SM, Zimmet PZ, et.al. The metabolic syndrome. Lancet 2005; 365: 1415–28.

Alberti KGMM, Zimmet P, Shaw J, et.al. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007; 24: 451–63.

Tuomilehto J, Lindstrom J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–50.

Chiasson J-L, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomised trial. Lancet 2002; 359: 2072–77.

Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

Scheen AJ, et.al. Is there a role for α-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003; 63: 933–51.

Van De Laar FA, Lucassen PL, Akkermans RP, et al. α-Glucosidase inhibitors for patients with type 2 diabetes. Diabetes Care 2005; 28: 154–63.

Matsumoto K, Yano M, Miyake S, et al. Effects of voglibose on glycemic excursions, insulin secretion, and insulin sensitivity in non-insulin-treated NIDDM patients. Diabetes Care 1998; 21: 256–60.

Matsumoto K, Sera Y, Abe Y, et al. Combination therapy of alpha-glucosidase inhibitor and a sulfonylurea compound prolongs the duration of good glycemic control. Metabolism 2002; 51: 1548–52.

Fujisawa T, Ikegami H, Inoue K, et al. Effect of two α-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms. Metabolism Clin Exp 2005;54:387-90.